Shots: The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent […]readmore
Tags : Agreement
Shots: Pevail and Lonza to work collaboratively for process and analytical development plus large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in […]readmore
Shots: Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) with Celltrion in Australia The […]readmore
Shots: Inflammasome to receive up to $160M up front, R&D milestone, commercialization milestone with royalties on sales of the developed product. The companies will co-develop up to three therapies for […]readmore
Shots: Ironwood to receive three non-contingent payment of $35M b/w 2021 & 2024, ~$90M as a milestone with royalties on sales of Linzess in China mainland, China Hong Kong and […]readmore
Shots: Tempus to receive milestones and royalties and has an option to fund part of product development programs in return of high royalty payments. Genmab and Tempus will jointly develop […]readmore
Shots: The companies collaborated to develop companion diagnostic utilizing Thermo Fisher’s Oncomine Dx Target Test for the identification of RET-altered NSCLC and thyroid cancer patients who may be treated with […]readmore
Shots: Gates Foundation to fund $55M which may extend up to $100M for the development of preclinical vaccine and immunotherapy candidates preventing HIV and tuberculosis infection. BioNTech will retain rights […]readmore
Shots: BMS & BioMotiv to form and fund new facilities, developing therapies for diseases with unmet medical needs and post identification of the candidate BMS has an option to acquire […]readmore
Shots: Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets following its approval in the EU and […]readmore